Horizon Therapeutics

Youtube Subscribe

Open: 111.15 Close: 111.6 Change: 0.45

How to know if Horizon Therapeutics is a risky investment without reading the whole internet.

The game is changing. There is a new strategy to evaluate Horizon Therapeutics fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Horizon Therapeutics are: Horizon, Therapeutics, Therapies, buy, HZNP, biotechnology, company, …

Concept Map

Semantic Network

Stock Summary

Horizon Therapeutics Public Limited Company focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases.

Today's Summary

Horizon Therapeutics (NASDAQ: HZNP) operates as a biotechnology company. 75 hedge fund portfolios held Horizon Therapedutics Public Limited Company at the end of fourth quarter.

Today's News

Horizon Therapeutics (NASDAQ: HZNP) operates as a biotechnology company. Horizon Therapies raised a total of $98M in its latest funding round. Horizon Therapeutics Plc (HZNP) stock price today is $111.55. In December 2022, Amgen (Nasdaq:AMGN) said it would scoop up Horizon Therapies for almost $28 billion. 75 hedge fund portfolios held Horizon Therapedutics Public Limited Company (NASDAQ:HZ NP) at the end of fourth quarter. California-based biotechnology company slightly increased its forecast for full-year 2023 revenue to range of $26.2 billion to $27.3 billion. Horizon Therapeutics Plc has accumulated a market cap worth $25.39 billion with P/E and price-to-earnings-growth ratios standing at 50.11 and 4.21 respectively. Pending acquisitions include Amgen buying Horizon Therapeutics for $27.8 billion, Pfizer buying Seagen for $43 billion and Merck buying Prometheus Biosciences for $10.8billion. Senior Medical Director, Clinical Development. Horizon Therapeutics plc to release first-quarter 2023 financial results on May 3, 2023. Horizon Therapies plc does not discriminate on the basis of race, color, religion, gender, gender.

Stock Profile

"Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland."

Keywords

This document will help you to evaluate Horizon Therapeutics without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Horizon Therapeutics are: Horizon, Therapeutics, Therapies, buy, HZNP, biotechnology, company, and the most common words in the summary are: horizon, therapeutic, job, stock, company, life, news, . One of the sentences in the summary was: 75 hedge fund portfolios held Horizon Therapedutics Public Limited Company at the end of fourth quarter.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #horizon #therapeutic #job #stock #company #life #news.

Read more →

Youtube Subscribe

---